Logo
x

Search

Subscribe Now

Advanced Neuroendocrine Tumors

Hutchmed Reports the US FDA's Acceptance of Surufatinib's NDA for Advanced Neuroendocrine Tumors

Hutchmed Reports the US FDA's Acceptance of Surufatinib's NDA for Advanced Neuroendocrine Tumors

  • July 2, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.